The Weill Cornell Urological Oncology Program has recently opened a new clinical trial for for men with metastatic castrate resistant prostate cancer (CRPC) whose cancer has gotten worse after other treatments. The study is evaluating an experimental drug called cabozantinib (XL184). The sponsor of the study is Exelixis, and the principal investigator at Weill Cornell is Dr. Himisha Beltran.
For more information about the study, please call Renee Khan, RN at (212) 746-1851, e-mail Renee at email@example.com.
- Metastatic castration-resistant prostate cancer
- Evidence of bone metastasis related to prostate cancer
- Must have received prior treatment with docetaxel and either abiraterone or MDV3100 and have had disease progression on each medication
- Detailed eligibility reviewed when you contact the study team
The purpose of the study is to determine if cabozantinib is effective in prolonging survival compared to the drug prednisone. The study will also evaluate the safety of cabozantinib and how well people with advanced prostate cancer tolerate the drug. In an ongoing study, cabozantinib treatment has resulted in high rates of pain relief and has shown substantial anti-tumor activity. Cabozantinib could provide a valuable new treatment option for men with CRPC who experience disease progression on or after prior therapies.
Study participants will be randomly assigned to one of two treatment groups:
- Group 1: cabozantinib once daily + placebo prednisone twice daily
- Group 2: Prednisone twice daily + placebo cabozantinib once daily
Participants have a 2/3 chance of receiving cabozantinib (Group 1) and a 1/3 chance of receiving prednisone (Group 2). Participants will not know which treatment they are receiving. Cabozantinib is a capsule and prednisone is a tablet, both taken by mouth.
Participants will continue to receive study treatment as long as they continue to receive clinical benefit and do not experience unacceptable side effects.
Click here to view all current prostate cancer clinical trials in the Department of Medicine.